BioSpace News Archive

BioStem Technologies Inc. announced that it has retained the services of Mr. Nick McCoy, who will lead BioStem’s Diabetic Foot Ulcer and Venous Leg Ulcer clinical trials process as a consultant to the Company.

SeaStar Medical Holding Corporation announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT.

SonoThera today announced that it will present four abstracts at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Baltimore, Maryland, May 7-11, 2024.

Tharimmune, Inc. announced that management will be participating in two investor conferences in May.

Neogen® Corporation announced the launch of the new Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium.

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”) today announced that it will present new data from its ongoing real-world registry study of Revita for T2D at the upcoming German Diabetes Association (DDG) Annual Meeting taking place May 8-11, 2024, in Berlin, Germany.

Nacuity Pharmaceuticals, Inc. today announced that the first patients have been implanted in the final cohort of the Phase 1/2 clinical trial evaluating NPI-002 for delayed cataract progression in patients undergoing vitrectomy.

Scenic Biotech announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.

MannKind Corporation announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.